Address
Email address
Phone number
Website
https://www.elitekliinik.eeElite erakliinikElite erakliinik Tartus Sangla 63. Viljatusravi ja günekoloogid, 3D-4D ultraheli, endokrinoloog, nahaarstid, kõrva-nina-kurguarstid, onkoloogid jpm. erialad
Name
AS Kliinik Elite
Registry code
10911961
VAT number
EE102150641
Type
AS - Joint Stock Company
Status
Registered
Foundation date
18.12.2002 (21)
Financial year
01.01-31.12
Capital
25 560.00 €
Activity
86221 - Provision of specialised medical treatment
3 241 133 €
268 364 €
8%
2 325 €
(estimate is approximate)
456 991 €
33
Submitted
No tax arrears
59%
36%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Andrei Sõritsa 25.11.1961 (62) | 100% - 25 560.00 EUR | Board member | Direct ownership | FounderShareholder |
| Deniss Sõritsa 16.11.1982 (41) | - | Board member | Member of a higher management body, i.e. board member or supervisory board member | |
| Katrin Sõritsa 10.11.1992 (32) | - | - | Member of a higher management body, i.e. board member or supervisory board member | Board member |
| Kristina Sõritsa 06.04.1983 (41) | - | - | Member of a higher management body, i.e. board member or supervisory board member | Board member |
| Reet Küüts 17.03.1948 (76) | - | - | Member of a higher management body, i.e. board member or supervisory board member | |
| Anne Vaiksaar 01.11.1972 (52) | - | - | - | Board member |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Celvia CC AS 11673707 | - | - | - | Founder |
| 2019 29.06.2020 | 2020 30.06.2021 | 2021 29.06.2022 | 2022 29.06.2023 | 2023 28.06.2024 | |
|---|---|---|---|---|---|
| Total Revenue | 2 143 398 € | 1 756 396 € | 2 358 599 € | 3 191 954 € | 3 241 133 € |
| Net profit (loss) for the period | 200 424 € | 64 747 € | 244 703 € | 257 765 € | 268 364 € |
| Profit Margin | 9% | 4% | 10% | 8% | 8% |
| Current Assets | 350 356 € | 155 545 € | 231 354 € | 346 286 € | 434 444 € |
| Fixed Assets | 488 583 € | 491 675 € | 490 755 € | 439 834 € | 316 244 € |
| Total Assets | 838 939 € | 647 220 € | 722 109 € | 786 120 € | 750 688 € |
| Current Liabilities | 187 526 € | 161 061 € | 291 247 € | 347 493 € | 293 697 € |
| Non Current Liabilities | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - |
| Share Capital | 25 560 € | 25 560 € | 25 560 € | 25 560 € | 25 560 € |
| Equity | 651 413 € | 486 159 € | 430 862 € | 438 627 € | 456 991 € |
| Employees | 39 | 31 | 30 | 32 | 33 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 15 308.2 € | 133 686.57 € | 130 934.96 € | 73 |
| 2023 Q4 | 25 023.49 € | 134 993.97 € | 127 438.71 € | 73 |
| 2023 Q3 | 18 337.5 € | 128 151.48 € | 126 352.44 € | 73 |
| 2023 Q2 | 19 192 € | 139 529.86 € | 125 402.28 € | 75 |
| 2023 Q1 | 29 324.9 € | 129 090.05 € | 117 660.43 € | 76 |
| 2022 Q4 | 24 912.25 € | 123 664.27 € | 105 133.14 € | 71 |
| 2022 Q3 | 10 074 € | 110 641.45 € | 105 170.29 € | 67 |
| 2022 Q2 | 18 501.8 € | 103 019.48 € | 96 408.26 € | 66 |
| 2022 Q1 | 20 949.1 € | 103 078.86 € | 97 605.56 € | 69 |
| 2021 Q4 | 19 980.4 € | 108 863.89 € | 88 124.41 € | 67 |
| 2021 Q3 | 19 459.5 € | 77 610.87 € | 75 188.06 € | 62 |
| 2021 Q2 | 18 743.7 € | 78 931.8 € | 73 105.09 € | 67 |
| 2021 Q1 | 14 024.08 € | 64 966.06 € | 66 165.75 € | 69 |
| 2020 Q4 | 17 214.6 € | 76 735.26 € | 70 934.08 € | 67 |
| 2020 Q3 | 13 595 € | 62 664.23 € | 58 462.14 € | 61 |
| 2020 Q2 | 3 630 € | 50 505.38 € | 48 179.22 € | 61 |
| 2020 Q1 | 10 665 € | 102 355.92 € | 71 268.09 € | 61 |
